Professor WENLIN HUANG, a senior professor at the Sun Yat-sen University Cancer
Center and Chief Scientist at Guangzhou Doublle Bioproduct Co., Ltd., enjoys the
State Council Special Government Allowance, is a selected talent under China’s Key
Talent Program, and has received the 7th National Invention Patent Gold Award. He
was also elected as a member of the European Academy of Sciences (2024) and is
among the top 100,000 scientists globally. Professor Huang is also the director of the Guangdong Provincial New Tumor Vaccine
Engineering Laboratory and the Guangdong Provincial Key Laboratory for the
Development of Targeted Tumor Therapeutic Drugs. He focuses on gene therapy drug
development, translational research, and tumor immunotherapy projects. From 1988
to 2001, he conducted research and academic work at prestigious institutions in the
United States, including the Higher Institute of Virus Research, the University of
Pennsylvania School of Medicine, and Princeton University. After returning to China in 2001, he joined the Sun Yat-sen University Cancer Center, where he served as the director of the Biological Therapy Center. He has led
numerous projects, including major new drug creation initiatives from the 11th to 13th
Five-Year Plans, 973 projects, and National Natural Science Foundation projects. As
the first author or corresponding author, he has published over 180 SCI papers in top
journals such as Nature Medicine, Nature Communications, PNAS, Gastroenterology, and JCI (H-index: 58). He holds 50 patents for inventions in the U.S., international
PCT, and China. He is the chief editor of national graduate textbooks such as
Molecular Virology (1st/2nd/3rd editions) and academic monographs like Signal
Transduction, Molecular Targeted Therapy of Cancer, Melanoma, and Principles of
Cancer Personalized Medicine. He also contributed to the national 8-year medical
curriculum textbook Oncology and Cancer Biotherapy. He has received numerous
awards, including the China National Science and Technology Progress Award
(Second Class, 2016), the Ministry of Education Natural Science First-Class Award
(2011), and the Guangdong Provincial Science and Technology Progress Award (First
Class, 2010, 2015). In the field of innovative drug translation, Professor Huang has made significant
achievements. With a broad international perspective, he continuously explores and
breaks through frontier technologies in drug innovation. He has successfully
translated a series of anti-cancer drug products, leading his team from laboratory
research to commercialization. He has pioneered several innovative products, including China’s first gene therapy drug (recombinant human endostatin adenovirus
injection) to complete Phase III clinical trials, gene therapy products (recombinant
human interferon adenovirus injection), and China’s first autologous natural killer cell
injection, multi-target oncolytic virus projects, CAR-NK, and stem cell-based
therapies, which have successfully met market demands. His research has been widely
reported by authoritative media such as China Central Television (CCTV), China
Education Television, and Scientific Chinese. In terms of social roles, he has served as a member of the Guangdong Province SARS
Prevention and Treatment Expert Committee, rotating president of the Asia-Pacific
Gene and Cell Therapy Association, vice president of the Guangzhou Overseas
Chinese Students Association, senior member of the American Gene and Cell Therapy
Association, consultant for the Ministry of Science and Technology’s “13th Five-Year” 973 Infectious Disease Program, and honorary professor at The Chinese University of
Hong Kong
